Public Employees Retirement System of Ohio lifted its holdings in shares of Celgene Co. (NASDAQ:CELG) by 1.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 601,520 shares of the biopharmaceutical company’s stock after acquiring an additional 11,416 shares during the period. Public Employees Retirement System of Ohio’s holdings in Celgene were worth $87,714,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Capital Counsel LLC NY lifted its holdings in shares of Celgene by 0.4% during the second quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock worth $214,000 after purchasing an additional 6 shares during the period. Fort Pitt Capital Group LLC lifted its holdings in shares of Celgene by 0.6% during the second quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock worth $250,000 after purchasing an additional 11 shares during the period. Savant Capital LLC lifted its holdings in shares of Celgene by 0.9% during the second quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 20 shares during the period. TCI Wealth Advisors Inc. lifted its holdings in shares of Celgene by 0.9% during the second quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock worth $395,000 after purchasing an additional 26 shares during the period. Finally, Granite Investment Advisors LLC lifted its holdings in shares of Celgene by 1.1% during the second quarter. Granite Investment Advisors LLC now owns 2,579 shares of the biopharmaceutical company’s stock worth $352,000 after purchasing an additional 29 shares during the period. Institutional investors and hedge funds own 78.93% of the company’s stock.

Several equities research analysts recently weighed in on the company. BTIG Research reaffirmed a “hold” rating on shares of Celgene in a report on Tuesday, January 23rd. Piper Jaffray Companies reissued a “neutral” rating and issued a $133.00 target price on shares of Celgene in a report on Monday, October 23rd. Cantor Fitzgerald set a $112.00 target price on Celgene and gave the company a “hold” rating in a report on Tuesday, January 23rd. Stifel Nicolaus reduced their target price on Celgene from $155.00 to $149.00 and set a “buy” rating for the company in a report on Friday, October 20th. Finally, Leerink Swann reissued a “buy” rating and issued a $120.00 target price on shares of Celgene in a report on Friday, December 22nd. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $130.35.

Celgene Co. (NASDAQ:CELG) opened at $95.16 on Thursday. The stock has a market capitalization of $74,920.00, a price-to-earnings ratio of 26.36, a PEG ratio of 0.68 and a beta of 1.49. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. Celgene Co. has a one year low of $92.85 and a one year high of $147.17.

Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.78 by $0.09. The business had revenue of $3.48 billion during the quarter, compared to the consensus estimate of $3.46 billion. Celgene had a return on equity of 64.14% and a net margin of 22.38%. The business’s revenue was up 16.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.61 EPS. research analysts forecast that Celgene Co. will post 7.68 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.watchlistnews.com/public-employees-retirement-system-of-ohio-increases-stake-in-celgene-co-celg/1851977.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.